Wyatt Luenenborg
About Wyatt Luenenborg
Wyatt Luenenborg is the Vice President of Marketing at BeiGene, with extensive experience in oncology marketing and a background in both marketing and sales within the biotechnology industry.
Vice President Marketing at BeiGene
Wyatt Luenenborg currently serves as the Vice President of Marketing at BeiGene. He has been with the company since January 2019. In this role, he leverages his extensive experience in oncology marketing to develop and implement marketing strategies, particularly focusing on the promotion of oncology treatments.
Previous Role at Genentech
Wyatt Luenenborg worked at Genentech in various capacities focusing on skin cancer and BioOncology treatments. From 2016 to 2019, he was the Director of National SKiN Cancer Sales for Erivedge, Cotellic, and Zelboraf. Prior to that, he was the Director of SKiN Cancer Marketing from 2015 to 2016, and the Director of Marketing for Erivedge from 2014 to 2015. He also served as the Associate Director BioOncology Commercial Pipeline from 2013 to 2014.
Experience at Genentech
Wyatt Luenenborg spent a significant portion of his career at Genentech, where he held multiple leadership roles over more than a decade. Between 2010 and 2013, he was the Group Product Manager, Strategy for Herceptin and Perjeta. Prior to that, from 2007 to 2010, he served as the Product Manager/Senior Product Manager for Herceptin, Perjeta, and Kadcyla Marketing. His work focused primarily on developing marketing strategies for various oncology drugs.
Educational Background
Wyatt Luenenborg studied at the University of Nebraska-Lincoln, where he achieved a Bachelor of Science in Soil Science and Agronomy. His academic background provides a solid foundation for his understanding of complex scientific and agricultural concepts, which he has leveraged throughout his career in biotechnology marketing.
Extensive Oncology Marketing Experience
Wyatt Luenenborg has a deep-rooted expertise in oncology marketing, particularly in skin cancer treatments. Over his career, he has worked on the marketing strategies for several significant cancer drugs including Erivedge, Cotellic, and Zelboraf. His roles have encompassed both marketing and sales, giving him a well-rounded perspective on the biotechnology industry.